Isabel Haferland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabel Haferland has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Pinter
Department of Dermatology, Venereology and Allergology, Clinical Research, University Hospital, Frankfurt am Main, Germany
2 shared publications - Anke König
Goethe University Frankfurt, University Hospital, Department of Dermatology, Venereology, and Allergology, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
2 shared publications - Claudia Buerger
Department of Dermatology, Venereology and Allergology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany
2 shared publications Andreas Pinter
Department of Dermatology, Venerology and Allergology University Hospital Frankfurt am Main Frankfurt am Main Germany
1 shared publicationAnke Koenig
Department of Dermatology, Venerology and Allergology University Hospital Frankfurt am Main Frankfurt am Main Germany
1 shared publication- Ann Christina Foldenauer
Department of Medical Statistics, University Hospital RWTH Aachen, Aachen, Germany
1 shared publication
Latest Publications
- Open Access
- 6 November 2024
- Published by S. Karger AG in Dermatology
- Vol. 241 (1) , 1-12
Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study
Introduction: Brodalumab, a human monoclonal antibody that selectively inhibits the interleukin (IL)-17 receptor subunit A, has been approved for the treatment of moderate-to-severe plaque psoriasis. The treatment benefit of brodalumab has been clearly demonstrated in multiple clinical studies. However, data on effectiveness for difficult-to-treat body regions, especially in everyday clinical practice, are still limited. Methods: In this exploratory observational clinical study, psoriasis patients suffering from nail and scalp involvement who received brodalumab during routine clinical care were enrolled at 7 centers in Germany. Patients were observed for over 60 weeks. The co-primary endpoints were 75% improvement in Psoriasis Scalp Severity Index (PSSI75) at week 12 and 75% improvement in Nail Psoriasis Severity Index (NAPSI75) at week 24. Secondary endpoints included assessment of general skin and disease outcomes, quality-of-life, and patient satisfaction with treatment. Results: Eighty-seven patients were included. Mean age was 46.8 years, 70.1% patients were male, and mean body mass index was 28.9 kg/m2. The co-primary endpoints were achieved by more than 90% of patients who met criteria for effectiveness analyses (n = 62): 93.6% of patients achieved PSSI75 at week 12 and 90.3% of patients achieved NAPSI75 at week 24. Median body surface area involvement improved from 14% at baseline to 1.5% and 1% at weeks 12 and 24, respectively. Median Dermatology Life Quality Index scores improved from 16 at baseline to 2 and 1 at weeks 12 and 24, respectively. Improvements were maintained in the majority of patients throughout the 60-week study. Brodalumab was well tolerated and patients were highly satisfied with the treatment. Conclusion: Outcomes assessed in this study, including assessments of scalp and nail symptoms, improved following initiation of brodalumab therapy. This study of psoriasis patients in a real-world setting supports the long-term clinical effectiveness of brodalumab on difficult-to-treat body regions.
- 6 November 2024
- Published by S. Karger AG in Dermatology
- Vol. 241 (1) , 1-12
Open AccessBrodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study
Introduction: Brodalumab, a human monoclonal antibody that selectively inhibits the interleukin (IL)-17 receptor subunit A, has been approved for the treatment of moderate-to-severe plaque psoriasis. The treatment benefit of brodalumab has been clearly demonstrated in multiple clinical studies. However, data on effectiveness for difficult-to-treat body regions, especially in everyday clinical practice, are still limited. Methods: In this exploratory observational clinical study, psoriasis patients suffering from nail and scalp involvement who received brodalumab during routine clinical care were enrolled at 7 centers in Germany. Patients were observed for over 60 weeks. The co-primary endpoints were 75% improvement in Psoriasis Scalp Severity Index (PSSI75) at week 12 and 75% improvement in Nail Psoriasis Severity Index (NAPSI75) at week 24. Secondary endpoints included assessment of general skin and disease outcomes, quality-of-life, and patient satisfaction with treatment. Results: Eighty-seven patients were included. Mean age was 46.8 years, 70.1% patients were male, and mean body mass index was 28.9 kg/m2. The co-primary endpoints were achieved by more than 90% of patients who met criteria for effectiveness analyses (n = 62): 93.6% of patients achieved PSSI75 at week 12 and 90.3% of patients achieved NAPSI75 at week 24. Median body surface area involvement improved from 14% at baseline to 1.5% and 1% at weeks 12 and 24, respectively. Median Dermatology Life Quality Index scores improved from 16 at baseline to 2 and 1 at weeks 12 and 24, respectively. Improvements were maintained in the majority of patients throughout the 60-week study. Brodalumab was well tolerated and patients were highly satisfied with the treatment. Conclusion: Outcomes assessed in this study, including assessments of scalp and nail symptoms, improved following initiation of brodalumab therapy. This study of psoriasis patients in a real-world setting supports the long-term clinical effectiveness of brodalumab on difficult-to-treat body regions.
- Open Access
- 27 February 2024
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 2024, 1-10
A Novel Epidermis Model Using Primary Hidradenitis Suppurativa Keratinocytes
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Patients can present with inflammatory nodules, abscesses up to fistulas, or sinus tracts in intertriginous body parts. Occlusion of the sebaceous gland unit leads to its rupture, with a subsequent exuberant immune response. Given there is still no causative therapy, to better understand HS and develop novel therapeutic concepts, research activities in the HS field are constantly growing. Primary skin cells, blood cells, and ex vivo explant cultures from HS patients have been previously used as HS cell culture models. In vitro reconstituted epidermal models are established to study inflammatory dermatoses, such as psoriasis or atopic dermatitis. For HS, the exploration of epidermis models would be an excellent addition, e.g., biomarkers or barrier function in testing new topic treatment options. We therefore established a stratified in vitro HS epidermis model based on primary cells from HS lesions. After isolating keratinocytes from lesional skin, we cultured them submerged in a transwell system. To induce differentiation, we then lifted them to the air-liquid interface. Immunohistochemical staining demonstrated that our HS-epidermis model meets the expected differentiation pattern. In addition, we detected the secretion of the inflammatory cytokines interleukin-1β and TNF-α.
- 27 February 2024
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 2024, 1-10
Open AccessA Novel Epidermis Model Using Primary Hidradenitis Suppurativa Keratinocytes
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Patients can present with inflammatory nodules, abscesses up to fistulas, or sinus tracts in intertriginous body parts. Occlusion of the sebaceous gland unit leads to its rupture, with a subsequent exuberant immune response. Given there is still no causative therapy, to better understand HS and develop novel therapeutic concepts, research activities in the HS field are constantly growing. Primary skin cells, blood cells, and ex vivo explant cultures from HS patients have been previously used as HS cell culture models. In vitro reconstituted epidermal models are established to study inflammatory dermatoses, such as psoriasis or atopic dermatitis. For HS, the exploration of epidermis models would be an excellent addition, e.g., biomarkers or barrier function in testing new topic treatment options. We therefore established a stratified in vitro HS epidermis model based on primary cells from HS lesions. After isolating keratinocytes from lesional skin, we cultured them submerged in a transwell system. To induce differentiation, we then lifted them to the air-liquid interface. Immunohistochemical staining demonstrated that our HS-epidermis model meets the expected differentiation pattern. In addition, we detected the secretion of the inflammatory cytokines interleukin-1β and TNF-α.
- Open Access
- 20 January 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (7) , 1005-1013
Mechanism of anti‐inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the hair follicles leading to painful lesions, associated with increased levels of pro‐inflammatory cytokines. Numerous guidelines recommend antibiotics like clindamycin and rifampicin in combination, as first‐line systemic therapy in moderate‐to‐severe forms of inflammation. HS has been proposed to be mainly an auto‐inflammatory disease associated with but not initially provoked by bacteria. Therefore, it has to be assumed that the pro‐inflammatory milieu previously observed in HS skin is not solely dampened by the bacteriostatic inhibition of DNA‐dependent RNA polymerase. To further clarify the mechanism of anti‐inflammatory effects of rifampicin, ex vivo explants of lesional HS from 8 HS patients were treated with rifampicin, and its effect on cytokine production, immune cells as well as the expression of Toll‐like receptor 2 (TLR2) were investigated. Analysis of cell culture medium of rifampicin‐treated HS explants revealed an anti‐inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)‐1β, IL‐6, IL‐8, IL‐10 and tumour necrosis factor (TNF)‐α production. Immunohistochemistry of the rifampicin‐treated explants suggested a tendency for it to reduce the expression of TLR2 while not affecting the number of immune cells.
- 20 January 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (7) , 1005-1013
Open AccessMechanism of anti‐inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the hair follicles leading to painful lesions, associated with increased levels of pro‐inflammatory cytokines. Numerous guidelines recommend antibiotics like clindamycin and rifampicin in combination, as first‐line systemic therapy in moderate‐to‐severe forms of inflammation. HS has been proposed to be mainly an auto‐inflammatory disease associated with but not initially provoked by bacteria. Therefore, it has to be assumed that the pro‐inflammatory milieu previously observed in HS skin is not solely dampened by the bacteriostatic inhibition of DNA‐dependent RNA polymerase. To further clarify the mechanism of anti‐inflammatory effects of rifampicin, ex vivo explants of lesional HS from 8 HS patients were treated with rifampicin, and its effect on cytokine production, immune cells as well as the expression of Toll‐like receptor 2 (TLR2) were investigated. Analysis of cell culture medium of rifampicin‐treated HS explants revealed an anti‐inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)‐1β, IL‐6, IL‐8, IL‐10 and tumour necrosis factor (TNF)‐α production. Immunohistochemistry of the rifampicin‐treated explants suggested a tendency for it to reduce the expression of TLR2 while not affecting the number of immune cells.